MEDICAL FACILITIES CORP (DR.CA) Stock Fundamental Analysis
Canada - TSX:DR - CA58457V5036 - Common Stock
14.55 CAD
-0.03 (-0.21%)
Overall DR gets a fundamental rating of 7 out of 10. We evaluated DR against 15 industry peers in the Health Care Providers & Services industry. DR gets an excellent profitability rating and is at the same time showing great financial health properties. DR is cheap, but on the other hand it scores bad on growth. This makes DR very considerable for value investing!
1. Profitability
1.1 Basic Checks
DR had positive earnings in the past year.
DR had a positive operating cash flow in the past year.
DR had positive earnings in 4 of the past 5 years.
DR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
DR's Return On Assets of 29.34% is amongst the best of the industry. DR outperforms 93.33% of its industry peers.
The Return On Equity of DR (105.57%) is better than 100.00% of its industry peers.
DR has a better Return On Invested Capital (16.22%) than 93.33% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DR is significantly above the industry average of 7.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.34% | ||
| ROE | 105.57% | ||
| ROIC | 16.22% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
1.3 Margins
DR's Profit Margin of 28.90% is amongst the best of the industry. DR outperforms 93.33% of its industry peers.
In the last couple of years the Profit Margin of DR has grown nicely.
Looking at the Operating Margin, with a value of 14.93%, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of DR has remained more or less at the same level.
DR has a Gross Margin of 65.05%. This is amongst the best in the industry. DR outperforms 93.33% of its industry peers.
DR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.93% | ||
| PM (TTM) | 28.9% | ||
| GM | 65.05% |
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DR is creating value.
The number of shares outstanding for DR has been reduced compared to 1 year ago.
The number of shares outstanding for DR has been reduced compared to 5 years ago.
Compared to 1 year ago, DR has an improved debt to assets ratio.
2.2 Solvency
DR has an Altman-Z score of 1.29. This is a bad value and indicates that DR is not financially healthy and even has some risk of bankruptcy.
DR has a Altman-Z score of 1.29. This is comparable to the rest of the industry: DR outperforms 60.00% of its industry peers.
The Debt to FCF ratio of DR is 1.88, which is an excellent value as it means it would take DR, only 1.88 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.88, DR belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.
DR has a Debt/Equity ratio of 1.25. This is a high value indicating a heavy dependency on external financing.
DR has a Debt to Equity ratio (1.25) which is comparable to the rest of the industry.
Even though the debt/equity ratio score it not favorable for DR, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 1.88 | ||
| Altman-Z | 1.29 |
ROIC/WACC1.81
WACC8.94%
2.3 Liquidity
DR has a Current Ratio of 1.58. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Current ratio value of 1.58, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
A Quick Ratio of 1.48 indicates that DR should not have too much problems paying its short term obligations.
DR has a better Quick ratio (1.48) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.48 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 193.02% over the past year.
DR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -37.06%.
The Revenue has been decreasing by -3.59% on average over the past years.
EPS 1Y (TTM)193.02%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%1100%
Revenue 1Y (TTM)-37.06%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-24.84%
3.2 Future
DR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.76% yearly.
Based on estimates for the next years, DR will show a decrease in Revenue. The Revenue will decrease by -7.10% on average per year.
EPS Next Y32.59%
EPS Next 2Y9.79%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue Next Year-21.98%
Revenue Next 2Y-11.46%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
DR is valuated reasonably with a Price/Earnings ratio of 8.27.
Based on the Price/Earnings ratio, DR is valued cheaply inside the industry as 93.33% of the companies are valued more expensively.
DR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.19.
A Price/Forward Earnings ratio of 9.17 indicates a reasonable valuation of DR.
Based on the Price/Forward Earnings ratio, DR is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.50, DR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.27 | ||
| Fwd PE | 9.17 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DR is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
93.33% of the companies in the same industry are more expensive than DR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.34 | ||
| EV/EBITDA | 4.23 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y9.79%
EPS Next 3Y10.76%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.44%, DR has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 3.09, DR pays a bit more dividend than its industry peers.
DR's Dividend Yield is comparable with the S&P500 average which is at 2.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.44% |
5.2 History
The dividend of DR decreases each year by -19.91%.
DR has been paying a dividend for at least 10 years, so it has a reliable track record.
DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
DR pays out 7.21% of its income as dividend. This is a sustainable payout ratio.
DP7.21%
EPS Next 2Y9.79%
EPS Next 3Y10.76%
TSX:DR (10/30/2025, 7:00:00 PM)
14.55
-0.03 (-0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.2%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap269.32M
Revenue(TTM)278.37M
Net Income(TTM)80.45M
Analysts42.22
Price Target16.58 (13.95%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.44% |
Yearly Dividend0.36
Dividend Growth(5Y)-19.91%
DP7.21%
Div Incr Years1
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.26%
Min EPS beat(2)-24.98%
Max EPS beat(2)-7.54%
EPS beat(4)1
Avg EPS beat(4)-8.64%
Min EPS beat(4)-41.75%
Max EPS beat(4)39.71%
EPS beat(8)2
Avg EPS beat(8)-39.68%
EPS beat(12)4
Avg EPS beat(12)4.47%
EPS beat(16)6
Avg EPS beat(16)-104.58%
Revenue beat(2)0
Avg Revenue beat(2)-4.32%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)-4.13%
Revenue beat(4)0
Avg Revenue beat(4)-8.01%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)-4.13%
Revenue beat(8)2
Avg Revenue beat(8)-4.04%
Revenue beat(12)3
Avg Revenue beat(12)-2.78%
Revenue beat(16)4
Avg Revenue beat(16)-2.75%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)50.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.27 | ||
| Fwd PE | 9.17 | ||
| P/S | 0.69 | ||
| P/FCF | 3.34 | ||
| P/OCF | 3.14 | ||
| P/B | 2.52 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.23 |
EPS(TTM)1.76
EY12.1%
EPS(NY)1.59
Fwd EY10.91%
FCF(TTM)4.36
FCFY29.95%
OCF(TTM)4.63
OCFY31.82%
SpS21.07
BVpS5.77
TBVpS-1.62
PEG (NY)0.25
PEG (5Y)N/A
Graham Number15.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.34% | ||
| ROE | 105.57% | ||
| ROCE | 19.63% | ||
| ROIC | 16.22% | ||
| ROICexc | 21.11% | ||
| ROICexgc | 52.76% | ||
| OM | 14.93% | ||
| PM (TTM) | 28.9% | ||
| GM | 65.05% | ||
| FCFM | 20.69% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 1.88 | ||
| Debt/EBITDA | 1.6 | ||
| Cap/Depr | 20.05% | ||
| Cap/Sales | 1.29% | ||
| Interest Coverage | 6.5 | ||
| Cash Conversion | 102.93% | ||
| Profit Quality | 71.58% | ||
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.48 | ||
| Altman-Z | 1.29 |
F-Score6
WACC8.94%
ROIC/WACC1.81
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)193.02%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%1100%
EPS Next Y32.59%
EPS Next 2Y9.79%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-37.06%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-24.84%
Revenue Next Year-21.98%
Revenue Next 2Y-11.46%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
EBIT growth 1Y-43.39%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year0.9%
EBIT Next 3Y1.6%
EBIT Next 5YN/A
FCF growth 1Y-0.32%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-10.39%
OCF growth 3Y3.26%
OCF growth 5Y1.55%
MEDICAL FACILITIES CORP / DR.CA FAQ
What is the fundamental rating for DR stock?
ChartMill assigns a fundamental rating of 7 / 10 to DR.CA.
What is the valuation status for DR stock?
ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.
Can you provide the profitability details for MEDICAL FACILITIES CORP?
MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for DR stock?
The Price/Earnings (PE) ratio for MEDICAL FACILITIES CORP (DR.CA) is 8.27 and the Price/Book (PB) ratio is 2.52.
Can you provide the dividend sustainability for DR stock?
The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 7.21%.